Translational Approaches in Regenerative Medicine

Abstract

Moving regenerative therapies from laboratory discovery to reliable clinical use has proven far harder than early enthusiasm suggested. Stem cell preparations that perform consistently in rodent injury models frequently disappoint in human trials, and the reasons -- donor variability, manufacturing inconsistency, immunological mismatch, and inadequate preclinical models -- are now well enough understood to be addressable. We evaluated five translational frameworks applied to 12,486 patients across 38 European clinical sites between 2016 and 2023, covering mesenchymal stem cell therapy, induced pluripotent stem cell-derived products, bioengineered scaffold-cell constructs, gene-edited autologous cell therapies, and extracellular vesicle-based treatments. Sites spanned Madrid, Zurich, Amsterdam, and Vienna. Each framework was scored against our Translational Readiness Index (TRI), which integrates manufacturing scalability, immunological safety, clinical efficacy, regulatory pathway clarity, and cost-effectiveness. Gene-edited autologous therapies achieved the highest TRI (0.912), driven by strong efficacy and safety profiles despite high per-patient manufacturing costs. Bioengineered scaffold constructs scored 0.887, excelling in structural tissue applications including cartilage and bone. Extracellular vesicle therapies (TRI 0.864) showed the most favourable manufacturing and safety profile but require standardised potency assays before broader deployment. Across all frameworks, regulatory pathway uncertainty and batch-to-batch manufacturing variation were the two factors most strongly associated with delayed or failed clinical translation.